{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:58:51Z","timestamp":1648907931514},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s10072-014-1742-4","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T01:11:06Z","timestamp":1401153066000},"page":"49-50","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The setting of a botulinum toxin treatment service"],"prefix":"10.1007","volume":"35","author":[{"given":"Maurizio","family":"Cavallini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,28]]},"reference":[{"issue":"5","key":"1742_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuro.2005.01.017","volume":"26","author":"KR Aoki","year":"2005","unstructured":"Aoki KR (2005) Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26(5):785\u2013793 (Epub 2005 Jul 5. Review)","journal-title":"Neurotoxicology"},{"issue":"7","key":"1742_CR2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793\u2013803. doi: 10.1177\/0333102410364676 (Epub 2010 Mar 17)","journal-title":"Cephalalgia"},{"issue":"9","key":"1742_CR3","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","volume":"50","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ (2010) Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 50(9):1406\u20131418. doi: 10.1111\/j.1526-4610.2010.01766.x","journal-title":"Headache"},{"key":"1742_CR4","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1002\/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4","volume":"6","author":"MF Brin","year":"1997","unstructured":"Brin MF (1997) Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 6:S146\u2013S168 (Review)","journal-title":"Muscle Nerve Suppl"},{"issue":"7","key":"1742_CR5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804\u2013814. doi: 10.1177\/0333102410364677 (Epub 2010 Mar 17)","journal-title":"Cephalalgia"},{"issue":"6","key":"1742_CR6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 50(6):921\u2013936. doi: 10.1111\/j.1526-4610.2010.01678.x (Epub 2010 May)","journal-title":"Headache"},{"issue":"1\u20132","key":"1742_CR7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0928-4257(01)00086-9","volume":"96","author":"FA Meunier","year":"2002","unstructured":"Meunier FA, Schiavo G, Molg\u00f3 J (2002) Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 96(1\u20132):105\u2013113","journal-title":"J Physiol Paris"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-014-1742-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-014-1742-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-014-1742-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T05:18:55Z","timestamp":1559107135000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-014-1742-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":7,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["1742"],"URL":"https:\/\/doi.org\/10.1007\/s10072-014-1742-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}